デフォルト表紙
市場調査レポート
商品コード
1555027

多汗症治療の世界市場調査レポート:産業分析、規模、シェア、成長、動向、予測、2024年~2032年

Global Hyperhidrosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032


出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
多汗症治療の世界市場調査レポート:産業分析、規模、シェア、成長、動向、予測、2024年~2032年
出版日: 2024年08月01日
発行: Value Market Research
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多汗症治療市場の世界需要は、2023年の6億9,317万米ドルから2032年にはほぼ11億6,021万米ドルの市場規模に達し、2024-2032年の調査期間においてCAGRで5.89%の成長が予測されています。

多汗症治療には、個人の生活の質に大きな影響を与える過剰な発汗を管理するための医学的および治療的アプローチが含まれます。多汗症は、手のひら、足の裏、脇の下、顔など体のさまざまな部位に影響を及ぼし、社会的不快感や機能障害につながります。治療の選択肢は、外用制汗剤や内服薬から、ボツリヌス毒素注射、イオントフォレーシス、外科的介入などの侵襲的な処置まで多岐にわたる。この治療は、過剰な発汗を抑え、症状を緩和し、全身の健康を改善することを目的としています。医療技術の進歩と症状に対する深い理解により、より効果的で的を絞った治療法が開発されています。

市場力学

多汗症治療市場は、いくつかの要因によって大きな成長を遂げています。多汗症の有病率の上昇に加え、この疾患に対する認識と診断の高まりが、効果的な治療オプションに対する旺盛な需要を生み出しています。ボツリヌス毒素の新規製剤や改良型イオントフォレーシス装置などの治療技術の進歩は、より効果的な症状管理を求める患者に新たなソリューションを提供しています。低侵襲処置の受け入れ拡大や、継続的モニタリングや標的治療のためのウェアラブル機器などの技術革新が、多汗症治療市場の拡大に寄与しています。

さらに、生活の質(QOL)と患者中心の治療が重視されるようになったことで、研究開発への投資が促進され、新たな治療法の選択肢が生まれています。遠隔医療や遠隔診察の拡大により、特に医療サービスが行き届いていない地域での治療アクセスが容易になります。さらに、製薬会社と研究機関の連携はイノベーションを促進し、利用可能な治療法の幅を広げます。しかし、先進治療の高額な費用と潜在的な副作用が、多汗症治療市場の成長を抑制する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、多汗症治療の世界市場における各セグメントを包括的に評価することもできます。多汗症治療業界の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

多汗症治療市場レポートのこのセクションでは、国および地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家が今後の機会で、それぞれの製品やサービスのターゲット層を特定するのに役立ちます。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東&アフリカにおける多汗症治療市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 多汗症治療- 産業分析

  • イントロダクション:市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 多汗症治療の世界市場分析:タイプ別

  • 概要:タイプ別
  • 実績・予測データ分析:タイプ別
  • 腋窩
  • 手掌
  • 足底
  • その他

第6章 多汗症治療の世界市場分析:治療別

  • 概要:治療別
  • 実績・予測データ分析:治療別
  • 外用薬
  • 経口薬(抗コリン薬、その他の経口薬)
  • ボツリヌス毒素注射
  • イオントフォレーシス
  • 外科的

第7章 多汗症治療の世界市場分析:年齢別

  • 概要:年齢別
  • 実績・予測データ分析:年齢別
  • 50歳未満
  • 50歳以上

第8章 多汗症治療の世界市場分析:エンドユーザー別

  • 概要:エンドユーザー別
  • 実績・予測データ分析:エンドユーザー別
  • 病院
  • 外来手術センター
  • 皮膚科クリニック
  • その他

第9章 多汗症治療の世界市場分析:地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米:セグメント別
    • 北米:国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州:セグメント別
    • 欧州:国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域:セグメント別
    • アジア太平洋地域:国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ:セグメント別
    • ラテンアメリカ:国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ:セグメント別
    • 中東・アフリカ:国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第10章 多汗症治療企業の競合情勢

  • 多汗症治療市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の発売
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AbbVie Inc.
  • Avanor Healthcare Ltd.
  • Brickell Biotech Inc.
  • Dermadry Laboratories Inc.
  • Dermavant Sciences Inc.
  • Hugel Inc.
  • Eirion Therapeutics Inc.
  • Eli Lilly And Company
  • Intas Pharmaceuticals Ltd.
  • Kaken Pharmaceutical Co. Ltd.
  • Maruho Co. Ltd.
  • MiraDry Inc
  • SweatBlock
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Type (USD MN)
  • Axillary Market Sales By Geography (USD MN)
  • Palmar Market Sales By Geography (USD MN)
  • Plantar Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Analysis By Treatment (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Oral Medication(Anticholinergics, Other Oral Medications) Market Sales By Geography (USD MN)
  • Botulinum Toxin Injections Market Sales By Geography (USD MN)
  • Iontophoresis Market Sales By Geography (USD MN)
  • Surgical Market Sales By Geography (USD MN)
  • Analysis By Age (USD MN)
  • Below 50 Years Market Sales By Geography (USD MN)
  • Above 50 Years Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Dermatology Clinics Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Hyperhidrosis Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Hyperhidrosis Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Hyperhidrosis Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Treatment
  • Market Attractiveness Analysis By Age
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Type (USD MN)
  • Axillary Market Sales By Geography (USD MN)
  • Palmar Market Sales By Geography (USD MN)
  • Plantar Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Market Analysis By Treatment (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Oral Medication(Anticholinergics, Other Oral Medications) Market Sales By Geography (USD MN)
  • Botulinum Toxin Injections Market Sales By Geography (USD MN)
  • Iontophoresis Market Sales By Geography (USD MN)
  • Surgical Market Sales By Geography (USD MN)
  • Global Market Analysis By Age (USD MN)
  • Below 50 Years Market Sales By Geography (USD MN)
  • Above 50 Years Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Dermatology Clinics Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112115575

The global demand for Hyperhidrosis Treatment Market is presumed to reach the market size of nearly USD 1160.21 Million by 2032 from USD 693.17 Million in 2023 with a CAGR of 5.89% under the study period 2024-2032.

Hyperhidrosis treatment involves medical and therapeutic approaches to manage excessive sweating, a condition significantly impacting an individual's quality of life. Hyperhidrosis can affect various body parts, including the palms, soles, underarms, and face, leading to social discomfort and functional impairment. Treatment options range from topical antiperspirants and oral medications to more invasive procedures such as botulinum toxin injections, iontophoresis, and surgical interventions. This treatment aims to reduce excessive sweating, alleviate symptoms, and improve overall well-being. Advances in medical technology and a deeper understanding of the condition have led to the development of more effective and targeted therapies.

MARKET DYNAMICS

The hyperhidrosis treatment market is experiencing significant growth driven by several factors. The rising prevalence of hyperhidrosis, combined with increased awareness and diagnosis of the condition, creates a robust demand for effective treatment options. Advances in treatment technologies, including novel formulations of botulinum toxin and improved iontophoresis devices, offer new solutions for patients seeking more effective management of their symptoms. The rising acceptance of minimally invasive procedures and technological innovations, such as wearable devices for continuous monitoring and targeted treatment, contribute to hyperhidrosis treatment market expansion.

Additionally, the increasing emphasis on quality of life and patient-centric care encourages investment in research and development, leading to new therapeutic options. Expanding telemedicine and remote consultations facilitates treatment access, particularly in underserved regions. Furthermore, collaborations between pharmaceutical companies & research institutions drive innovation and broaden the range of available treatments. However, the high cost of advanced treatments and potential side effects may restrain hyperhidrosis treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Hyperhidrosis Treatment. The growth and trends of Hyperhidrosis Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Hyperhidrosis Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Axillary
  • Palmar
  • Plantar
  • Other

By Treatment

  • Topical
  • Oral Medication(Anticholinergics, Other Oral Medications)
  • Botulinum Toxin Injections
  • Iontophoresis
  • Surgical

By Age

  • Below 50 Years
  • Above 50 Years

By End-user

  • Hospitals
  • Ambulatory Surgical Centers
  • Dermatology Clinics
  • Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hyperhidrosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hyperhidrosis Treatment market include AbbVie Inc., Avanor Healthcare Ltd., Brickell Biotech Inc., Dermadry Laboratories Inc., Dermavant Sciences Inc., Hugel Inc., Eirion Therapeutics Inc., Eli Lilly And Company, Intas Pharmaceuticals Ltd., Kaken Pharmaceutical Co. Ltd., Maruho Co. Ltd., MiraDry Inc, SweatBlock. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. HYPERHIDROSIS TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Treatment
    • 3.7.3 Market Attractiveness Analysis By Age
    • 3.7.4 Market Attractiveness Analysis By End-user
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY TYPE

  • 5.1. Overview By Type
  • 5.2. Historical and Forecast Data Analysis By Type
  • 5.3. Axillary Historic and Forecast Sales By Regions
  • 5.4. Palmar Historic and Forecast Sales By Regions
  • 5.5. Plantar Historic and Forecast Sales By Regions
  • 5.6. Other Historic and Forecast Sales By Regions

6. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY TREATMENT

  • 6.1. Overview By Treatment
  • 6.2. Historical and Forecast Data Analysis By Treatment
  • 6.3. Topical Historic and Forecast Sales By Regions
  • 6.4. Oral Medication(Anticholinergics, Other Oral Medications) Historic and Forecast Sales By Regions
  • 6.5. Botulinum Toxin Injections Historic and Forecast Sales By Regions
  • 6.6. Iontophoresis Historic and Forecast Sales By Regions
  • 6.7. Surgical Historic and Forecast Sales By Regions

7. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY AGE

  • 7.1. Overview By Age
  • 7.2. Historical and Forecast Data Analysis By Age
  • 7.3. Below 50 Years Historic and Forecast Sales By Regions
  • 7.4. Above 50 Years Historic and Forecast Sales By Regions

8. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY END-USER

  • 8.1. Overview By End-user
  • 8.2. Historical and Forecast Data Analysis By End-user
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 8.5. Dermatology Clinics Historic and Forecast Sales By Regions
  • 8.6. Other Historic and Forecast Sales By Regions

9. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE HYPERHIDROSIS TREATMENT COMPANIES

  • 10.1. Hyperhidrosis Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF HYPERHIDROSIS TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. AbbVie Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Avanor Healthcare Ltd.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Brickell Biotech Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Dermadry Laboratories Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Dermavant Sciences Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Hugel Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Eirion Therapeutics Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Eli Lilly And Company
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Intas Pharmaceuticals Ltd.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Kaken Pharmaceutical Co. Ltd.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Maruho Co. Ltd.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. MiraDry Inc
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. SweatBlock
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies